BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 1.15B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.36M |
| Shares Out | 23.05M |
| EPS (ttm) | -3.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $47.32 |
| Previous Close | $48.07 |
| Change ($) | -0.75 |
| Change (%) | -1.56% |
| Day's Open | 47.50 |
| Day's Range | 46.65 - 47.92 |
| Day's Volume | 473,866 |
| 52-Week Range | 14.79 - 64.63 |
High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first...
BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead ...
Company to present corporate update and plans for 2021
Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic s...
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intellig...
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2020 Results - Earnings Call Transcript
Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021
Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”)
Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)
NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
Fifth potential indication for BXCL501, an orally dissolving thin film Fifth potential indication for BXCL501, an orally dissolving thin film
BioXcel product candidates use the 505(b)(2) approval pathway. Successful pivotal trials for two indications in acute agitation.
Today, we look at a promising CNS play called BioXcel Therapeutics. The shares have lost more than a third from their pre-secondary offering highs.
With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at wha...
In 2020, the central nervous system (CNS) market has largely failed to keep up with $IBB.
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intellige...
BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript
Investors were not impressed with the company's latest quarterly update.
SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligen...
NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announce...
NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announce...
The company reported positive results from two pivotal clinical trials.
Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high. The post Biox...
Highly statistically significant improvements in PEC score observed vs. placebo (p
Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation Company providing BXCL501 to evaluate its activ...
Patent is expected to extend IP protection until 2039 Patent is expected to extend IP protection until 2039
Will lead global clinical development strategy and medical affairs for the Company’s neuroscience programs Will lead global clinical development strategy and medical affairs for the Company’s ...
Here's why investors shouldn't bet on these two companies long-term, at least not yet.
Former Allergan Commercial Head to lead commercialization efforts for BXCL501 across multiple neuropsychiatric disorders Former Allergan Commercial Head to lead commercialization efforts for B...
NEW HAVEN, Conn., June 15, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intell...
The 2020 year is practically halfway done, and this has really been the year of the biotech.
Topline results expected in the first quarter of 2021 Topline results expected in the first quarter of 2021
Topline results, expected in July of 2020, are intended to support a New Drug Application filing Topline results, expected in July of 2020, are intended to support a New Drug Application filing
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript
Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020
Clinical trial successes could send shares of these drugmakers screaming higher.
BioXcel Therapeutics (NASDAQ: BTAI) founder and CEO Dr. Mehta Vimal spoke with Benzinga about its BXCL-501 drug candidate for agitation in Alzheimer's patients — and how it relates to wearable...
More than one-third of the SERENITY I & II patients have been dosed, including over 100 bipolar patients
Unlike much of the market, BioXcel Therapeutics is actually up year to date.
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript
Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia
Shares tumble after the company announces that it is raising capital.
Can these soaring biotech stocks keep climbing?
One reason that investors continue to do business with full-service brokerage firms is they generate researched and studied investment ideas.
Company is preparing to initiate Phase 1b/2 RELEASE trial Company is preparing to initiate Phase 1b/2 RELEASE trial
BioXcel Therapeutics: AI-Focused Biopharmaceutical Player For 2020
When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.
Topline results expected in mid-2020 Topline results expected in mid-2020
BXCL701 may improve patient response when combined with checkpoint inhibitors or re-sensitize patients who have failed checkpoint therapy BXCL701 may improve patient response when combined wit...
About BTAI
BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaborat... [Read more...]
| Industry Biotechnology | IPO Date Mar 8, 2018 |
| CEO Vimal Mehta | Employees 40 |
| Stock Exchange NASDAQ | Ticker Symbol BTAI |
Analyst Forecasts
According to 7 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is 112.00, which is an increase of 136.69% from the latest price.